Isoray, Inc. announced that William Cavanagh III was terminated from his position of Chief Research and Development Officer of the Company on February 7, 2023.
Perspective Therapeutics, Inc.
Equities
CATX
US46489V1044
Medical Equipment, Supplies & Distribution
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.735 USD | -0.29% | -5.16% | +334.08% |
01:52pm | RBC Starts Perspective Therapeutics With Outperform Rating, $3 Price Target | MT |
May. 09 | Cantor Fitzgerald Starts Perspective Therapeutics With Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+334.08% | 1.02B | |
-5.76% | 182B | |
+2.03% | 111B | |
-3.49% | 68.48B | |
+1.17% | 49.69B | |
+7.95% | 44.46B | |
+2.33% | 40.67B | |
+23.45% | 31.22B | |
+0.49% | 26.09B | |
+15.30% | 25.32B |
- Stock Market
- Equities
- CATX Stock
- News Perspective Therapeutics, Inc.
- Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer